Gemcitabine - An alternative mentioned One Researcher went on about this drug - being available (only to his colleagues it seems) as alternative. While countering the claim of there being few choices.
No defense - no rebuttle !!!
Sorry to say we could have used a more persuasive and defensive team... Very weak indeed.
Gemcitabine - six relevant randomised trials were identified with the number of patients randomised in each trial varying from 30 to 341 (total 704). All trials compared gemcitabine to active controls and varied in the reporting of outcomes. One study compared a single post-operative instillation of intravesical gemcitabine with a saline placebo in 341 patients and found no significant difference in the rates of tumour recurrence (28% versus 39%, respectively) or recurrence-free survival (HR (hazard ratio) 0.95, 95% CI 0.64 to1.39, P = 0.77). The rate of progression to invasive disease was greater with gemcitabine (2.4% versus 0.8%). A further trial compared gemcitabine with intravesical mitomycin C and demonstrated that the rates of recurrence (28% versus 39%) and progression (11% versus 18%) were lower with gemcitabine but did not reach statistical significance
Plus it's off label so no reimbursement - NO Contest!!!